Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Current Assets (2016 - 2025)

AC Immune has reported Current Assets over the past 11 years, most recently at $121.0 million for Q4 2025.

  • Quarterly Current Assets fell 38.36% to $121.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $121.0 million through Dec 2025, down 38.36% year-over-year, with the annual reading at $121.0 million for FY2025, 38.36% down from the prior year.
  • Current Assets was $121.0 million for Q4 2025 at AC Immune, down from $142.2 million in the prior quarter.
  • Over five years, Current Assets peaked at $243.9 billion in Q1 2021 and troughed at $97.6 million in Q3 2023.
  • The 5-year median for Current Assets is $166.8 million (2022), against an average of $52.1 billion.
  • Year-over-year, Current Assets plummeted 99.94% in 2022 and then skyrocketed 106012.48% in 2023.
  • A 5-year view of Current Assets shows it stood at $219.8 billion in 2021, then plummeted by 99.94% to $133.0 million in 2022, then skyrocketed by 106012.48% to $141.1 billion in 2023, then tumbled by 99.86% to $196.3 million in 2024, then plummeted by 38.36% to $121.0 million in 2025.
  • Per Business Quant, the three most recent readings for ACIU's Current Assets are $121.0 million (Q4 2025), $142.2 million (Q3 2025), and $159.2 million (Q2 2025).